Skip to content
Government NSW, Medical Health Aged Care

*** MEDIA ALERT *** Uniting NSW.ACT available for comment after Drug Summit in Lismore today

Uniting NSW.ACT < 1 mins read

*** MEDIA ALERT ***

Uniting NSW.ACT’s General Manager of Advocacy & External Relations Emma Maiden is available for comment following the NSW Drug Summit in Lismore today:

Speaking after this morning’s session, she said:

“Many of the issues outlined by those who attended day one of the drug summit in Griffith are being echoed by the people from Lismore and the NSW Northern Rivers region speaking on day two.

“They have reflected on the ongoing trauma being felt right across their community and on how many have either started or returned to using drugs as a way to deal with their pain.

“Stigma and fear of discrimination and judgement are key barriers when it comes to seeking help, along with a lack of joined up support services and treatment options.

“There has been a heartfelt plea to understand that people who use drugs are not bad. They deserve empathy and kindness and recognition of the bravery involved in taking steps to seek treatment.

“A call for a health and wellbeing response to drug use, not a criminal response drew a rousing cheer from those in the room.”

Please contact Andrew Bradley (Uniting NSW.ACT) 0481 064 379 or Sofie Wainwright 0403 920 301 to arrange interviews.

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:
  • Government VIC, Medical Health Aged Care
  • 08/12/2025
  • 07:53
Public Health Association of Australia

Five VicHealth former chairs urge government retain the health promotion foundation

Open letter to the Victorian Premier, Treasurer, and Health Minister (Issued by the Public Health Association of Australia on the authors' behalf). 8 December 2025 As five former Chairs ofVicHealth, representing a broad political spectrum and different eras of VicHealth’s work, we write to ask you to reconsider your Government’s decision to abolish VicHealth and place its important preventative health functions in the Health Department.We believe the decision is misguided and will fail to deliver the hoped-for savings. Abolishing VicHealth will severely reduce the effectiveness of important and innovative public health work in this State. Even with the best intentions,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.